BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...from Beijing Jacobio Pharmaceutical Co. Ltd.; RMC-4630 from Sanofi (Euronext:SAN; NASDAQ:SNY) and Revolution Medicines Inc. (NASDAQ:RVMD); and TNO155...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

...in combination with the pharma's Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitor, TNO155...
...teamed up with Novartis AG (NYSELNVS; SIX:NOVN) to combine MRTX849 with the pharma's SHP-2 inhibitor TNO155...
BioCentury | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

...respectively. Novartis’ SHP099 is in preclinical testing for cancer; the pharma also has SHP-2 inhibitor TNO155...
BioCentury | Jul 11, 2019
Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

...MRTX849, a KRAS G12C inhibitor that is in Phase I/II testing, with Novartis’ SHP-2 inhibitor, TNO155...
...SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 BioCentury Staff isatuximab (SAR650984) MRTX849 teprotumumab (HZN-001, RV001, r1507, rg1507) TNO155 Eisai...
BioCentury | Dec 12, 2018
Distillery Therapeutics

Cancer

...leukemia, B cell lymphoma and lung cancer. Novartis AG has two SHP-2 inhibitors in development: TNO155...
BioCentury | Aug 16, 2018
Distillery Therapeutics

Dermatology; pulmonary

...inhibition in animal models of other types of fibrosis. Novartis AG has the SHP-2 inhibitor TNO155...
BioCentury | Jun 12, 2018
Emerging Company Profile

A Cancer Target Revolution

...the clinic by year-end. Only one other company is developing an SHP-2 inhibitor: Novartis has TNO155...
...mutations in KRAS and BRAF. Revolution declined to comment on how its RMC-4630 differs from TNO155...
...nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss.” bioRxiv (2017) Elizabeth S. Eaton, Staff Writer TNO155 Novartis...
BioCentury | Apr 27, 2018
Financial News

Nextech leads Revolution Medicines' $56M series B

...million (see BioCentury, Dec. 22, 2016) . Novartis AG (NYSE:NVS; SIX:NOVN) is evaluating SHP-2 inhibitor TNO155...
...homology protein tyrosine phosphatase 1 (SHP-1) (SHPTP1) (PTPN6) Src homology protein tyrosine phosphatase 2 (SHP-2) (SHPTP2) (PTPN11) RMC-4630 TNO155...
BioCentury | Apr 27, 2018
Finance

Revolution revamp

...SHPTP1; PTPN6) and eukaryotic translation initiation factor 4E binding protein 1 (eIF4EBP1). Jaime de León, Staff Writer TNO155 Nextech...
BioCentury | Apr 24, 2018
Financial News

Nextech leads Revolution Medicines' $56M series B

...see BioCentury Extra, Dec. 20, 2016) . Novartis AG (NYSE:NVS; SIX:NOVN) is evaluating SHP-2 inhibitor TNO155...
...homology protein tyrosine phosphatase 1 (SHP-1) (SHPTP1) (PTPN6) Src homology protein tyrosine phosphatase 2 (SHP-2) (SHPTP2) (PTPN11) RMC-4630 TNO155...
Items per page:
1 - 10 of 10